



UNIVERSITY of CALIFORNIA, SAN DIEGO  
SCHOOL OF MEDICINE

July 31, 2007

Allen F. Gant  
CEO and Chairman of the Board  
BioMarck Pharmaceuticals  
2619 St. Mary's Street  
Raleigh, NC 27609

Patricia W. Finn, M.D.  
*Professor of Medicine*  
*Kenneth M. Moser Endowed Chair*  
*Director,*  
*Pulmonary and Critical Care*  
*Medicine*  
pwfinn@ucsd.edu

Dear Mr. Gant:

I am delighted to write a letter in strong support of Dr. Ken Adler and the research involving MARCKS-directed peptides.


I am a division director for pulmonary and critical care medicine and an investigator in immune mediated pulmonary disease. Thus, I can attest to Dr. Adler's outstanding reputation as a leader in pulmonary biology, as well as the potential importance for this area of investigation.

Increased mucous secretion presents a severe problem for patients with a number of pulmonary disorders including, but not limited to, COPD, asthma and cystic fibrosis. The lack of effective therapies for mucous hypersecretion compels examination of alternative pathways. As demonstrated by Dr. Adler's publications in the most prestigious journals (Nature Medicine, JBC, and JAP), the peptides that Dr. Adler describes are shown to effectively improve pulmonary functions in models of mucous hypersecretion. Thus, Dr. Adler has potential to greatly influence the care and clinical course of a number of debilitating pulmonary diseases.

In addition to Dr. Adler's creativity as a scientist, he is known for leadership qualities. In particular, by his studies of mucous secretion at both the basic and clinical levels are quite innovative, Dr. Adler embodies the type of translational investigator who has the potential to induce paradigm shifts in our understanding of pulmonary biology.

I enthusiastically support Dr. Adler and his innovative line of investigation.

Sincerely,

  
Patricia W. Finn, M.D.